Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Fa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Circulation
Glavni autori: Kosiborod, Mikhail N., Jhund, Pardeep S., Docherty, Kieran F., Diez, Mirta, Petrie, Mark C., Verma, Subodh, Nicolau, Jose C., Merkely, Béla, Kitakaze, Masafumi, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Lindholm, Daniel, Niklasson, Anna, Sjöstrand, Mikaela, Langkilde, Anna Maria, McMurray, John J.V.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2020
Teme:
Original Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964869/
https://ncbi.nlm.nih.gov/pubmed/31736335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items